The role of HDL-cholesterol in preventing atherosclerotic disease
|
|
|
- Sophie Harper
- 6 years ago
- Views:
Transcription
1 European Heart Journal Supplements (2005) 7 (Supplement F), F4 F8 doi: /eurheartj/sui036 The role of HDL-cholesterol in preventing atherosclerotic disease Philip Barter* The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney 2050, Australia KEYWORDS HDL-cholesterol; Atherosclerosis; Inflammation; Cardiovascular risk; Dyslipidaemia The cholesterol required by peripheral tissues, including vascular cells, is provided both by new synthesis in the cells and by a delivery from low-density lipoproteins (LDLs). When the level of LDLs is high, they accumulate in the artery wall where they are oxidized and taken up by foam cells in a process that leads to the development and progression of atherosclerosis. High-density lipoproteins (HDLs) oppose atherosclerosis directly, by removing cholesterol from foam cells, by inhibiting the oxidation of LDLs, and by limiting the inflammatory processes that underlie atherosclerosis. HDLs also have antithrombotic properties. Thus, HDL-cholesterol interrupts the process of atherogenesis at several key stages. Introduction Cardiovascular disease remains the world s leading cause of death, with age-standardized annual cardiovascular death rates ranging from about 60/ in Japan to / in Russia and the former Soviet Republics. 1 Preventing atherosclerosis holds the key to reduce the burden of cardiovascular disease, and a detailed understanding of the pathophysiology of atherosclerotic disease will facilitate the design of innovative therapeutic strategies for the management of dyslipidaemia and the prevention of morbid cardiovascular events. The relative contributions of individual lipoproteins to overall cardiovascular risk have been intensively studied over the last several decades. The role of LDLs in causing atherosclerosis is well known. It is also well known that HDLs protect against the disease. For example, as long ago as 1976, the Framingham study showed that depressed levels of HDL-cholesterol were significantly and independently associated with an increased risk of coronary death, 2 a finding confirmed by further analyses based on longer follow-up. 3,4 Further, cohort studies have strengthened the association between low HDL-cholesterol and adverse coronary 5 and cerebrovascular 6 outcomes. Recent studies have shown *Corresponding author. Tel: þ ; fax: þ address: p.barter@hri.org.au that low HDL-cholesterol is common in the insulinresistant states, such as the metabolic syndrome and type 2 diabetes, and may account for a substantial portion of the excess cardiovascular disease observed in patients with these conditions. 7 It is important to understand the complex and multifactorial ways in which HDLs protect the vasculature. This review provides an overview of plasma lipoproteins and atherosclerosis with particular reference to the role of HDLs. Overview of lipid metabolism Normal metabolism The liver secretes very low-density lipoproteins (VLDLs) that are rich in triglyceride and relatively poor in cholesterol (Figure 1 ). The endothelial enzyme, lipoprotein lipase, converts much of the triglycerides in VLDLs to free fatty acids, which are used by peripheral tissues as an energy source. As a result, the VLDL particle is converted first to an intermediate-density lipoprotein and then to an LDL particle. LDLs (the main cholesterol carrier in blood) are cholesterol-rich and triglyceridepoor when compared with VLDLs. LDLs deliver cholesterol to peripheral tissues, where it contributes to the synthesis and maintenance of cell membranes. & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oupjournals.org
2 HDL-cholesterol and atherosclerosis F5 surface charge. Most of the HDL particles in the circulation are spherical in shape and have a surface charge producing alpha migration. Insulin resistance and atherosclerosis Figure 1 Overview of lipoprotein metabolism with special reference to the role of HDL-cholesterol. FC, free (unesterified) cholesterol; CE, cholesterol ester; TG, triglyceride; FFA, free fatty acids; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LPL, lipoprotein lipase. Reproduced with permission from Barter PJ, Brewer HB Jr, Chapman MJ et al. 11 Most extrahepatic cells (with the exception of those synthesizing steroid hormones) are unable to metabolize cholesterol, which would therefore accumulate if supply exceeded demand. HDLs are the principal means by which excess cholesterol is removed from extrahepatic cells. The major apolipoprotein (apo) of HDLs, apoa-i, is secreted from the liver in a lipid-poor form. Once in plasma, it rapidly acquires lipids to be converted into an HDL particle via several mechanisms. The initial reaction is with a membrane transporter termed the ATP binding cassette transporter A-1 (ABCA1). 8 This mediates the transfer of phospholipids and some unesterified cholesterol from the peripheral cell to generate a nascent, disc-shaped HDL particle. This HDL disc then acquires further unesterified cholesterol from other plasma lipoproteins and from cell membranes. ApoA-Imediated activation of the enzyme, lecithin cholesterol acyltransferase (LCAT), results in the esterification of the free cholesterol to form a spheroidal HDL particle containing a core of cholesterol ester. 9 In addition, apoa-i-containing particles may fuse with apo-a-iicontaining particles to form spherical HDLs containing both apolipoproteins. HDL particles dispose of their load of cholesterol either by returning it directly to the liver via the scavenger receptor SR-B1 for excretion in bile or for recycling, 10 or by indirectly transferring it to the VLDL/LDL fraction in a process mediated by cholesteryl ester transfer protein (CETP). The cholesterol transferred to other lipoproteins by CETP may then be delivered to the tissues (including the liver) by the LDL-receptor. This CETP-mediated transfer of cholesterol from HDLs to the VLDL/LDL fraction may be pro-atherogenic by delivering cholesterol from the protective HDLs to the pro-atherogenic VLDL/LDL particles. The effects of pharmacologic inhibition of CETP are currently under clinical investigation, 11 although treatments based on this mechanism will not be available for several years. The complexity of these interactions renders HDL particles highly heterogeneous in their shape, size, and Lipolysis in fat cells is normally effectively suppressed by insulin in the fed state. In insulin-resistant individuals, lipolysis persists despite post-prandial increases in circulating insulin concentrations, leading to an increased release of free fatty acids. A proportion of these free fatty acids is transported to the liver, where they promote an increased synthesis of triglycerides, an increased production of the triglyceride-rich VLDLs, and an increase in the secretion of these particles into the plasma. The increased pool of VLDLs provides a larger pool of acceptors of the cholesterol transferred from both HDLs and LDLs into VLDLs. This transfer is accompanied by a reciprocal transfer of triglyceride into LDLs and HDLs, which therefore become enriched in triglyceride. Hydrolysis of the triglyceride in LDLs and HDLs by hepatic lipase reduces their particle size and generates small, dense LDLs and small, dense HDLs. Small, dense LDLs are especially prone to oxidation and thus more likely to be taken up by macrophages in the artery wall, leading to further progression of the atherosclerotic plaque. Pathophysiology of atherogenesis Atherosclerosis is an inflammatory disorder that may be initiated by several factors. One of the most important factor is LDLs. LDLs enter the artery wall from plasma. They may also return to the plasma. However, if the plasma level of LDLs exceeds a threshold, they enter the artery faster than they can be removed and thus accumulate. When they accumulate, they become modified, including being oxidized. The modified LDLs then stimulate endothelial cells to express a protein, monocyte chemotactic protein-1 (MCP-1), that attracts monocytes from the blood into the artery wall. The modified LDLs also promote the differentiation of monocytes into macrophages. Macrophages, in turn, express scavenger receptors to take up the modified LDLs, resulting in the formation of lipid-filled foam cells, the hallmark cells of atherosclerosis. Macrophages express a range of cytokines, including tumour necrosis factor-alpha (TNF-a) and interleukin-1, both of which activate endothelial cells to express the adhesion molecules, E-selectin, VCAM-1, and ICAM-1. These adhesion proteins bind plasma monocytes to the endothelium where they are then attracted into the artery wall by MCP-1. Thus, the entry of LDLs into the artery wall begins a cycle that both commences atherosclerosis but also leads to its progression. Figure 2 shows the role of LDLs in these early stages of atherosclerosis. It also shows the points at which HDLs oppose this process (described subsequently).
3 F6 P. Barter Figure 2 Principal steps in early atherogenesis. Stages opposed by HDLcholesterol are shown in white text on a black background. Reproduced with permission from Barter PJ, Nicholls S, Rye KA et al. Antiinflammatory properties of HDL. Circ Res 2004;95: Anti-atherogenic properties of HDL-cholesterol Removal of excess lipids from the vascular wall by HDLcholesterol is a key anti-atherogenic mechanism of HDL-cholesterol, as described earlier. However, atherogenesis is more than a straightforward over-supply of cholesterol to vascular cells, and several other important mechanisms are involved. These are shown schematically in Figure 2, and the involvement of HDLs in inhibiting these processes is described as follows. Inhibition of monocyte adhesion Endogenous, 12 purified, 13,14 or reconstituted HDLs, 15,16 or HDL-associated lysosphingolipids (sphingosylphosphorylcholine or lysosulfatide), 17 have been shown to inhibit the expression of E-selectin or other adhesion molecules by vascular endothelial cells exposed to cytokines. The results of one of these studies, 15 in which human vascular endothelial cells were exposed to TNFa in the presence and absence of a reconstituted HDLs, are shown in Figure 3. The TNFa-induced increase in the expression of both E-selectin and VCAM-1 was powerfully inhibited by exposure to HDLs. This reduced expression of adhesion molecules has also been shown to result in decreased binding of inflammatory cells, which is consistent with functional inhibition of atherosclerosis. 16 Further, supportive evidence for these anti-atherogenic mechanisms of HDLs is available from clinical studies, in which increased levels of adhesion molecules correlated with low HDL-cholesterol levels Interruption of a signalling pathway involving generation of sphingosine-1-phosphate by sphingosine kinase has been proposed as a mechanism for the beneficial effects of HDL-cholesterol on the expression of adhesion molecules. 21 Sphingosine-1-phosphate is involved in mediating endothelial activation and adhesion molecule expression in response to certain cytokines. Figure 3 Inhibition of TNFa-induced expression of the endothelial adhesion molecules, VCAM-1, and E-selectin by a reconstituted form of HDL-cholesterol. Drawn from data presented by Clay MA, Pyle DH, Rye KA et al. 15 C-reactive protein is a marker of systemic inflammation but may also play a more direct role in mediating inflammation during atherogenesis. The influence of both native human HDL and a reconstituted apoa-i-containing version on C-reactive protein-induced expression of adhesion molecules was evaluated in cultured human vascular endothelial cells in vitro. 22 Physiological concentrations of native HDLs and low concentrations of the reconstituted HDLs effectively abolished the increased expression of E-selectin, ICAM-1, and VCAM-1 (Figure 4 ). These effects appeared to arise via a novel mechanism distinct from those previously described, by which HDLs inhibit the expression of adhesion molecules by cytokines. Inhibition of LDL-cholesterol oxidation and MCP-1 expression Oxidized LDLs are a potent inducer of MCP-1 expression within the developing atherosclerotic plaque. HDLs contain an enzyme, paraoxonase, which is believed to confer protection against oxidation of LDL-cholesterol in the artery wall. HDLs with and without paraoxonase were incubated with an endothelial cell line in the presence of LDL-cholesterol. 23 The paraoxonasecontaining HDLs significantly protected LDL-cholesterol from oxidation and inhibited expression of MCP-1, whereas the paraoxonase-deficient species were without effect on either parameter. Co-cultures of human arterial endothelial cells with smooth muscle cells provide a useful model for evaluating the effects of HDL-cholesterol on monocyte recruitment. One study, involving incubation of such a co-culture with lipoproteins and human serum, showed that LDL-cholesterol induced a marked increase in the expression of MCP-1, and a seven-fold increase in the rate of migration of monocytes into the sub-endothelial space of the co-culture. 24 Addition of purified human HDLs to the LDLs reduced the rate of monocyte infiltration by 90%.
4 HDL-cholesterol and atherosclerosis F7 Figure 4 Native human HDL-cholesterol and apoa-i-containing reconstituted HDL-cholesterol inhibit the increase in E-selectin expression induced by C-reactive protein. Per cent inhibitions were calculated from mean levels of expression of E-selectin before and after exposure to HDL-cholesterol and/or C-reactive protein (mean expression after stimulation by C-reactive protein ¼ 100%). Drawn from data presented by Wadham C, Albanese N, Roberts J et al. 22 Similarly, potentially beneficial effects of HDLcholesterol have been demonstrated in human subjects. A study in women evaluated the relationships between the plasma lipid profile and expression of the CCR2 receptor, which mediates the binding of monocytes to the MCP-1 receptor. 25 In women with low LDL-cholesterol, variations in HDL levels had little effect on CCR2 expression. However, in a subset of patients with high LDL-cholesterol, low HDL-cholesterol was significantly associated with increased CCR2 expression (Figure 5 ). There was a significant inverse correlation between HDL-cholesterol levels and CCR2 expression in women with high LDL-cholesterol (r ¼ 20.62, P ¼ 0.028). Treatment of women who had isolated low cholesterol with oestrogen improved both the LDL-cholesterol/ HDL-cholesterol ratio and approximately halved CCR2 expression. Antithrombotic properties of HDL-cholesterol The final event in the evolution of a myocardial infarction or stroke is the generation of an occlusive intra-arterial thrombus. Thus, agents that reduce the coagulability of the blood, either through improved fibrinolysis or through reduced platelet aggregation, may prevent or delay a cardiovascular event. The fibrinolytic capacity of the blood is determined by the balance of activities of tissue plasminogen activator, which normally removes intravascular fibrin and its endogenous inhibitor, plasminogen activator inhibitor-1 (PAI-1). Elevated PAI-1 is often part of the cluster of metabolic risk factors associated with the metabolic syndrome, as is low HDLcholesterol. It is perhaps not surprising, therefore, that low HDL-cholesterol has been shown to correlate with elevated PAI-1 in humans. 26 A further observational study in 60 hypercholesterolaemic men showed that both levels of fibrinogen and Figure 5 Relationship between levels of HDL-cholesterol and expression of the CCR2 receptor, which recognizes the MCP-1, in women with low and high LDL-cholesterol. Significantly different from other groups (P, 0.05, Mann Whitney U test). Drawn from data presented by Han KH, Han KO, Green SR et al. 25 an index of platelet aggregability were significantly associated with reduced levels of the anti-atherogenic HDL sub-fraction-2 (HDL 2 ). 27 Moreover, platelet aggregability was significantly associated with low HDL 2 on multivariate analysis. A study in 132 men without history of cardiovascular disease confirmed the relationship between HDL 2 -cholesterol concentration and fibrinogen levels. 28 The level of HDL 2 -cholesterol, but not that of total HDL-cholesterol or HDL 3 -cholesterol, was significantly lower in men with the highest quartile of fibrinogen compared with the other three quartiles. Triglycerides and VLDL-cholesterol were also significantly associated with fibrinogen levels. Conclusions Mounting clinical and experimental evidence shows that HDLs exert multiple anti-atherogenic and antithrombotic effects that together are consistent with a marked reduction in the risk of a morbid cardiovascular event. Indeed, the epidemiological, clinical, and experimental evidence supporting an anti-atherogenic role for HDL-cholesterol is now overwhelming. These findings support the use of therapeutic strategies to counter the common finding of low HDL-cholesterol in patients with dyslipidaemia. References 1. World Health Organisation figures for org (October 2004). 2. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62: Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8: Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:
5 F8 P. Barter 5. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17: Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28: Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003;4: Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 2003;23: Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33: Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23: Barter PJ, Brewer HB Jr, Chapman MJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23: Cockerill GW, Huehns TY, Weerasinghe A et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1- induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103: Cockerill GW, Saklatvala J, Ridley SH et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999;19: Cockerill GW, Rye KA, Gamble JR et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15: Clay MA, Pyle DH, Rye KA et al. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 2001;157: Moudry R, Spycher MO, Doran JE. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 1997;7: Nofer JR, Geigenmuller S, Gopfert C et al. High density lipoproteinassociated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun 2003;310: Lupattelli G, Marchesi S, Lombardini R et al. Mechanisms of highdensity lipoprotein cholesterol effects on the endothelial function in hyperlipemia. Metabolism 2003;52: Hernandez C, Lecube A, Barbera G et al. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit 2003;9:CR114 CR Calabresi L, Gomaraschi M, Villa B et al. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2002;22: Xia P, Vadas MA, Rye KA et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999;274: Wadham C, Albanese N, Roberts J et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004;109: Mackness B, Hine D, Liu Y et al. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318: Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88: Han KH, Han KO, Green SR et al. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res 1999;40: Eggesbo JB, Hjermann I, Hostmark AT et al. Lipopolysaccharideinduced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein. Thromb Res 1993;70: Razavian SM, Atger V, Giral P et al. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. Arterioscler Thromb 1994;14: Halle M, Berg A, Keul J et al. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 1996;16:
High density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
Lipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different
Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
Chapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
Pathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam
Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain
Lipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)
Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
Acetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol
Lipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
Summary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS Patrick M. Moriarty, M.D., FACP, Director, Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical
Chapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
PPAR history of research
PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
INCREASED SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IS ASSOCIATED WITH A REDUCTION IN PERIPHERAL MONOCYTE COUNT
INCREASED SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IS ASSOCIATED WITH A REDUCTION IN PERIPHERAL MONOCYTE COUNT IN NORMAL INDIVIDUALS Zei-Shung Huang, 1 Kwan-Lih Hsu, 1 Kuo-Liong Chien, 1 Tien-Chun
Cholesterol Metabolism
Cholesterol Metabolism Lippincott s Illustrated Review Chapter 18 Steroid Nucleus 1 2 Cholesterol was isolated from gall bladder stones in 1774 3 Sources and Elimination of Cholesterol Synthesis: 1000
Lipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
Nature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
Lipids digestion and absorption, Biochemistry II
Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very
Arteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL
CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL You will notice that the endogenous pathway is very similar to the exogenous pathway What is the average daily amount of triacylglycerol
2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT
5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT Prof. Victor Blaton, Ph.D. Department of Clinical Chemistry, Hospital AZ Sint-Jan
Glossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
Dyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
Child born in year /3 will die before parents in US (diabetes)
Child born in year 2000-1/3 will die before parents in US (diabetes) ATP III identified 6 components of the metabolic syndrome that relate to CVD 1. Abdominal obesity 2. Atherogenic dyslipidemia (elevated
Thematic review series: The Immune System and Atherogenesis
thematic review Thematic review series: The Immune System and Atherogenesis Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? Alan Chait, 1 Chang Yeop Han, John
Are the effects of statins on HDL-cholesterol clinically relevant?
European Heart Journal Supplements (2004) 6 (Supplement C), C58 C63 Are the effects of statins on HDL-cholesterol clinically relevant? M.J. Chapman National Institute for Health and Medical Research (INSERM),
Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University
Adipose Tissue as an Endocrine Organ Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Functions of Adipose Tissue Adipose tissue expresses and secretes a variety of bioactive peptides,
Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia
Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary
Inflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
Cholesterol and its transport. Alice Skoumalová
Cholesterol and its transport Alice Skoumalová 27 carbons Cholesterol - structure Cholesterol importance A stabilizing component of cell membranes A precursor of bile salts A precursor of steroid hormones
Annals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome. James Kyle Taylor
Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome by James Kyle Taylor A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of
Metabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL
PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL Lipids are characterized by low polarity and limited solubility in water. Their plasma concentration is about 500-600
METABOLISM of ADIPOSE TISSUE
METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation
Niacin Metabolism: Effects on Cholesterol
Niacin Metabolism: Effects on Cholesterol By Julianne R. Edwards For Dr. William R. Proulx, PhD, RD Associate Professor of Nutrition and Dietetics In partial fulfillments for the requirements of NUTR342
ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
HDL : A Treatment Target? ESC Paris M. John Chapman Ph.D., D.Sc., FESC. President, European Atherosclerosis Society
ESC Paris 2011 HDL : A Treatment Target? M. John Chapman Ph.D., D.Sc., FESC Director, Dyslipidemia and Atherosclerosis Research Unit, INSERM, University Pierre and Marie Curie, Hôpital de la Pitié-Salpetriere,
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,
Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes
Atherosclerosis 137 Suppl. (1998) S13 S17 Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes Michael C. Phillips *, Kristin L. Gillotte, M. Page Haynes, William
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
JMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP
Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA
Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice
Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice Atherosclerosis, 2007 Chiba T, Shinozaki S, Nakazawa T, et al. Present by Sudaporn Pummoung Apolipoprotein E (apoe( apoe)
Zuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
The apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
LIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI
LIPID METABOLISM Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI Lipid metabolism is concerned mainly with fatty acids cholesterol Source of fatty acids from dietary fat de novo
Lipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia
Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies
CardioGenomicPlus Profile
CardioGenomicPlus Profile Patient: SAMPLE PATIENT DOB: Sex: MRN: Apo E Chromosome 19 APOE APO E2: cys / cys APO E3: cys / arg APO E4: arg / arg The two SNPs lead to 3 possible variants for each chromosome,
Cardiology, CardioVascular Center University Hospital Zurich Zurich, Switzerland
Modification of by the lipoxidation product malondialdehyde leads to LOX-1 dependent activation of endothelial PKCbeta-2 and adverse endothelial effects of in patients with coronary artery disease Christian
SUMMARY. Introduction. Study design. Summary
SUMMARY Introduction The global prevalence of type 2 diabetes is increasing rapidly and nowadays affects almost 250 million people. Cardiovascular disease is the most prevalent complication of type 2 diabetes,
Increasing HDL: the torcetrapib story
HOT TOPICS Cardiology Journal 2007, Vol. 14, No. 1, pp. 1 5 Copyright 2007 Via Medica ISSN 1507 4145 Increasing HDL: the torcetrapib story Grażyna Zaręba Department of Environmental Medicine, University
Inflammation plays a major role in atherosclerosis, 1 and
Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte
C h a p t e r 1 9 Protective HDL Cholesterol : Modalities to Elevate it
C h a p t e r 1 9 Protective HDL Cholesterol : Modalities to Elevate it PC Manoria 1, Pankaj Manoria 2, SK Parashar 3 1 Former Professor and Head, Department of Cardiology, GMC, Bhopal, M.P. 2 Senior Resident,
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
Zei-Shung Huang and Bor-Luen Chiang 1
CORRELATION BETWEEN SERUM LIPID PROFILES AND THE RATIO AND COUNT OF THE CD16+ MONOCYTE SUBSET IN PERIPHERAL BLOOD OF APPARENTLY HEALTHY ADULTS Zei-Shung Huang and Bor-Luen Chiang 1 Background and Purpose:
Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
Quantitative Real-Time PCR was performed as same as Materials and Methods.
Supplemental Material Quantitative Real-Time PCR Quantitative Real-Time PCR was performed as same as Materials and Methods. Expression levels in the aorta were normalized to peptidylprolyl isomerase B
Lipids, lipoproteins and cardiovascular disease
Lipids, lipoproteins and cardiovascular disease Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy Cardiovascular disease Plasma enzymes
The Study of Endothelial Function in CKD and ESRD
The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:
Lipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS. Kamsiah Jaarin, Nafeeza MI*
REVIEW ARTICLE Malaysian Journal of Medical Sciences, Vol. 6, No. 2, July 1999 (5-11) EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS Kamsiah Jaarin,
Dipartimento di Scienze Cliniche Luigi Sacco SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE
Dipartimento di Scienze Cliniche Luigi Sacco SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE DOTTORATO DI RICERCA IN NUTRIZIONE SPERIMENTALE E CLINICA CICLO XXIII TESI
A Study of Omega-3 Fatty Acid. Therapy in Patients with. Nephrotic Syndrome
A Study of Omega-3 Fatty Acid Therapy in Patients with Nephrotic Syndrome Dr Samira Siddiqui Renal Unit Glasgow Royal Infirmary Thesis for the degree of MD, Faculty of Medicine, University of Glasgow Submitted
Hypertriglyceridemia, Inflammation, & Pregnancy
Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of
REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School
Low Endothelial Shear Stress Upregulates Atherogenic and Inflammatory Genes Extremely Early in the Natural History of Coronary Artery Disease in Diabetic Hyperlipidemic Juvenile Swine Michail I. Papafaklis,
The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
Introduction REVIEW. M. John Chapman*, Wilfried Le Goff, Maryse Guerin, and Anatol Kontush. Keywords
European Heart Journal (2010) 31, 149 164 doi:10.1093/eurheartj/ehp399 REVIEW Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin,
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins
Review Article Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins A. R. Tall From the Division of Molecular Medicine, Department
Vulnerable Plaque. Atherothrombosis
Vulnerable Plaque Nuove acquisizioni sull'aterosclerosi: placca vulnerabile Marina Camera Dip. Scienze Farmacologiche, Facoltà di Farmacia, Università degli Studi di Milano & Laboratorio di Biologia Cellulare
Copyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
Triglyceride determination
Triglyceride determination Introduction: - Triglycerides are esters of fatty acids and are hydrolyzed to glycerol and free fatty acids (by lipase) - Triglyceride determinations when performed in conjunction
13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
La Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
Hans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
Prof. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty
STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE OF LIPIDS AND LIPOPROTEINS DEFINTITION: Compounds Insoluble in water But
ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ
ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ ΘΩΜΑΣ ΠΑΠΑΔΟΠΟΥΛΟΣ, MD, PHD ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΙΑΤΡΙΚΟ ΔΙΑΒΑΛΚΑΝΙΚΟ ΚΕΝΤΡΟ Inflammation as a cause of disease has entered the popular imagination. Diet ( macronutrients )
New promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport
DOI: 10.4149/BLL_2013_037 Bratisl Lek Listy 2013; 114 (3) REVIEW New promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport Ginter E 1, Simko V 2 Institute of Preventive